Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Umbralisib

ebbdff3f-9053-56dd-9ce8-a7471c6506be · FDA Approval Withdrawn · targets CK1EPSILON, PI3K

Umbralisib

MeasuredReference

Umbralisib targets RAF1, JAK1, JAK2. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RAF1JAK1JAK2YSK4_MAP3K19C_KIT

Top hallmarks

  • tumor promoting inflammation3.4k
  • proliferation2.0k
  • immune evasion2.0k

Top pathways disrupted

No pathway data.

Resistance landscape — Umbralisib

MeasuredReference

2 known oncogenic variants exist on Umbralisib's top targets — see detail for inhibition impact.

Open in new tab